Quick Highlights for Investors:
- Argenx (ARGX, Financial) has received FDA approval for Vyvgart Hytrulo, enabling self-injection for autoimmune disorders.
- Wall Street analysts forecast a significant upside for argenx SE (ARGX), with an average price target of $726.52.
- GuruFocus estimates a potential 276.3% upside based on the GF Value metric.
The U.S. Food and Drug Administration (FDA) has granted approval to Argenx's (ARGX) groundbreaking product, Vyvgart Hytrulo, which allows for self-administration. This innovative formulation, crafted in collaboration with Halozyme Therapeutics (HALO), provides a convenient subcutaneous injection option designed to address conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Analyst Price Targets and Recommendations
According to projections from 24 analysts, the average one-year price target for argenx SE (ARGX, Financial) stands at $726.52. This figure includes a high estimate of $1,100.00 and a low estimate of $416.00. The current estimate suggests a potential upside of 33.09% from the present price of $545.89. For more granular forecast data, investors are encouraged to visit the argenx SE (ARGX) Forecast page.
The consensus recommendation from 25 brokerage firms places argenx SE (ARGX, Financial) in the "Outperform" category, with an average recommendation score of 1.6. This scoring system ranges from 1 to 5, where 1 signifies a Strong Buy and 5 indicates a Sell rating.
GF Value Evaluation
According to GuruFocus, the projected GF Value for argenx SE (ARGX, Financial) in the next year is pegged at $2054.21, which translates to an impressive upside of 276.3% from the current market price of $545.89. The GF Value is a proprietary GuruFocus metric that estimates the fair trading value of a stock. It is derived from historical trading multiples, past business growth, and future performance forecasts. For more comprehensive data, please refer to the argenx SE (ARGX) Summary page.
